In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy - 02/04/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Baricitinib has been suggested as a promising therapy for COVID-19. |
• | Baricitinib modulates in vitro SARS-CoV-2-specific-response in a whole blood platform. |
• | Baricitinib decreases viral-specific-response mainly in mild/moderate COVID-19. |
Abstract |
Objective |
Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects, we in-vitro evaluated the impact of baricitinib on the SARS-CoV-2-specific-response using the whole-blood platform.
Methods |
We evaluated baricitinib effect on the IFN-γ-release and on a panel of soluble factors by multiplex-technology after stimulating whole-blood from 39 COVID-19 patients with SARS-CoV-2 antigens. Staphylococcal Enterotoxin B (SEB) antigen was used as a positive control.
Results |
In-vitro exogenous addition of baricitinib significantly decreased IFN-γ response to spike- (median: 0.21, IQR: 0.01–1; spike+baricitinib 1000 nM median: 0.05, IQR: 0–0.18; p < 0.0001) and to the remainder-antigens (median: 0.08 IQR: 0–0.55; remainder-antigens+baricitinib 1000 nM median: 0.03, IQR: 0–0.14; p = 0.0013). Moreover, baricitinib significantly decreased SEB-induced response (median: 12.52, IQR: 9.7–15.2; SEB+baricitinib 1000 nM median: 8, IQR: 1.44–12.16; p < 0.0001). Baricitinib did modulate other soluble factors besides IFN-γ, significantly decreasing the spike-specific-response mediated by IL-17, IL-1β, IL-6, TNF-α, IL-4, IL-13, IL-1ra, IL-10, GM-CSF, FGF, IP-10, MCP-1, MIP-1β (p ≤ 0.0156). The baricitinib-decreased SARS-CoV-2-specific-response was observed mainly in mild/moderate COVID-19 and in those with lymphocyte count ≥1 × 103/µl.
Conclusions |
Exogenous addition of baricitinib decreases the in-vitro SARS-CoV-2-specific response in COVID-19 patients using a whole-blood platform. These results are the first to show the effects of this therapy on the immune-specific viral response.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Keywords : Baricitinib, SARS-CoV-2, COVID-19, IGRA, Specific immune-response
Plan
Vol 82 - N° 4
P. 58-66 - avril 2021 Retour au numéro
Article précédent
- HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women
- Selena Alonso, Marta Vidal, Gemma Ruiz-Olalla, Raquel González, Chenjerai Jairoce, M. Nelia Manaca, Miquel Vázquez-Santiago, Reyes Balcells, Anifa Vala, María Rupérez, Pau Cisteró, Laura Fuente-Soro, Evelina Angov, Ross L. Coppel, Benoit Gamain, David Cavanagh, James G. Beeson, Arsenio Nhacolo, Esperança Sevene, John J. Aponte, Eusébio Macete, Ruth Aguilar, Alfredo Mayor, Clara Menéndez, Carlota Dobaño, Gemma Moncunill
- SARS-CoV-2 infections in children following the full re-opening of schools and the impact of national lockdown: Prospective, national observational cohort surveillance, July-December 2020, England
- Anna A Mensah, Mary Sinnathamby, Asad Zaidi, Laura Coughlan, Ruth Simmons, Sharif A Ismail, Mary E Ramsay, Vanessa Saliba, Shamez N Ladhani
Bienvenue sur EM-consulte, la référence des professionnels de santé.